Results 221 to 230 of about 98,417 (285)

Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma. [PDF]

Biomed Rep
Kidoikhammouan S, Mahalapbutr P, Ma-In P, Lert-Itthiporn W, Deenonpoe R, Suriya U, Wongkham S, Seubwai W.   +7 more
europepmc   +1 more source

Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Abstract To investigate the molecular mechanism by which gemcitabine (GEM) inhibits ovarian cancer (OC) progression, focusing on the hypoxia‐inducible factor 1‐alpha (HIF1A)/UBR5/LATS2 axis and Hippo pathway. Bioinformatics analysis of gene expression omnibus datasets identified HIF1A‐associated modules.
Jin Zhang, Lixia Xu, Kai Guo, Weijia Dong, Xin Dai, Donghua Gu   +5 more
wiley   +1 more source

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer. [PDF]

BJUI Compass
Hanna J, Fu MZ, Inan B, Guevara D, Lannan L, Patel D, Hemmati Ghavshough M, Golombos D, Jang T, Ghodoussipour S, Packiam VT.   +10 more
europepmc   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages. [PDF]

Oncogene
Pietrobono S, De Vita V, Mangiameli D, Aparo A, Lorenzo ES, Bonato A, Bertolini M, Scarlato E, Casalino S, Quinzii A, Zecchetto C, Melisi D.   +11 more
europepmc   +1 more source

Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Advanced‐stage ovarian cancers exhibit significant variability in responses to standard chemotherapy ranging from platinum‐refractory to platinum‐sensitive cancers. While genomic testing reveals tissue heterogeneity, it rarely provides actionable data for guiding therapy.
Chiara Maestri, Ivan Trus, Rajeshwar Nitiyanandan, Jahanvi Kumar, Ricardo J. Parker, Orazio De Tommasi, William Cance, Christian Apfel   +7 more
wiley   +1 more source

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus‐Associated Disorders

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Kaposi sarcoma herpes virus (KSHV) is associated with multiple clinical manifestations, including primary effusion lymphoma, an aggressive CD38+ B cell lymphoma with a plasmablastic phenotype. Case This case describes an antiretroviral therapy‐adherent person with HIV who presented with concurrent KSHV‐related disorders of Kaposi ...
Kandice Roberts, Paula Valiño Ramos, Saurabh Jindal, Vikas Prasad, Yi Shan Lee, Mariam Khanfar, Obi L. Griffith, Malachi Griffith, Jeanne Jiang, Ethel Cesarman, Daniel Rauch, Paul Simonson, Thomas Odeny, Lee Ratner   +13 more
wiley   +1 more source

Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2). [PDF]

Front Immunol
Wang X, Zhang P, Cao D, Xu H.
europepmc   +1 more source

Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with most patients presenting with advanced disease. Surgical resection remains the only potentially curative option, yet recurrence rates are high. Case We present a rare case of metachronous primary pancreatic neuroendocrine tumor (PanNET) and PDAC in a 71‐year‐old ...
Anastasia S. Fatyanova, Maria E. Kalinina, Dina F. Islamova, Igor O. Shchekoturov, Julia V. Lerner, Nadezhda A. Stashevskaya, Pavel Burko, Ilias Miltiadis   +7 more
wiley   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl, Elaine Del Nery, Pierre Gestraud, Maral Halladjian, Elodie Girard, Adèle Soria, Elodie Anthony, Leanne De Koning, Nicolas Servant, Els Berns, Maud Kamal   +10 more
wiley   +1 more source